Core Viewpoint - The company, Xiansheng Pharmaceutical (2096.HK), experienced a significant drop in stock price, falling over 7% to HKD 13.04, following the announcement of a share placement to raise funds for research and operational needs [1] Group 1: Fundraising Details - The company announced a placement of 121 million shares, representing approximately 4.66% of the enlarged share capital [1] - The placement price is set at HKD 12.95 per share, which is an 8.03% discount compared to the closing price of HKD 14.08 from the previous day [1] - The total funds raised are expected to be HKD 15.67 billion [1] Group 2: Use of Proceeds - Approximately 90% of the net proceeds, amounting to HKD 15.54 billion, will be allocated for research and development expenses [1] - The funds will support clinical research for new drugs in both China and the United States, aiming to accelerate the development process [1] - The remaining 10% of the proceeds will be used for working capital and other general corporate purposes to sustain the company's daily operations and long-term development needs [1]
港股异动丨先声药业放量跌超7%，先旧后新折价配股筹资